In the News Pyrexar HT Hyperthermia

enfrdehija

Pyrexar Medical Buys Back Outside Ownership

new building introPyrexar Medical today purchased back all outstanding third party interest in the Utah based corporation.  

In April of 2015, Pyrexar Medical purchased the hyperthermia assets from Perseon Medical, which included the BSD-500 Superficial /Interstitial Hyperthermia System and the BSD-2000 Deep Regional Hyperthermia Systems.  In the original purchase agreement, Perseon Medical maintained a 19.9% interest in Pyrexar, along with royalties on future product sales.

In an agreement reached today, Pyrexar purchased back all Perseon held interests including all current and future royalty payments. “With the expected growth of Pyrexar Medical, we felt this was a great opportunity to retain full ownership of the company” said Pyrexar CEO, Mark Falkowski. “We should see significant return on this investment”.

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR Hyperthermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.
 
To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com

Pyrexar brings Cancer Treatment Options to Taiwan

mackay memorial hospitalTaiwan now treating cancer patients with Hyperthermia in New Taipei City

After passing the rigorous clearance process with the TFDA, (Taiwan Food and Drug Administration), a Pyrexar BSD-2000 Deep Regional Hyperthermia system is now installed and treating patients at MacKay Memorial Hospital in New Taipei City, Taiwan. Hyperthermia cancer treatment involves localized heating of cancer tumors using RF energy to a target temperature of 42˚C.  This process is clinically proven to make cancer cells more sensitive to chemotherapy, radiotherapy, and immunotherapy treatments.

On-site to provide hands-on training, and treat the first series of patients, was well-respected physician and researcher Dr. Jacobi van der Zee from Erasmus University Hospital-Daniel den Hoed Cancer Center Rotterdam, The Netherlands. Dr. van der Zee is recognized as a world leader in hyperthermia with a long list of published papers and clinical studies.

The news quickly reached nearby hospitals creating lines of doctors and clinicians daily to see the new device in action.  Integral to bringing this life-saving treatment to Taiwan was the team from Lindenbiotech and its president Tainang Huang, Ph.D.  “Having this first installation on the island is important to the health and wellbeing of the people of Taiwan,” says Dr. Huang “Cancer is a very serious threat to our population which now exceeds 23 million and effects 1 in every 223 people”.  

Mainland China has embraced hyperthermia in the treatment of cancers for over 20 years.  “We are hopeful that this first of several installations planned for Taiwan this year will begin to positively affect the people of that region.,” says Mark Falkowski, CEO Pyrexar Medical. “

ABOUT LINDENBIOTECH:
Lindenbiotech is the exclusive distributor for Pyrexar Hyperthermia products in Taiwan.  Offering site planning, installation, service, and support. lindenbiotech.com

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR Hyperthermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.
 
To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com.

Spain Warming to the Use of Hyperthermia in Cancer Treatment

magna sign 2016Using hyperthermia to treat disease is not new for the peoples of Spain. Like many European nations, thermal therapy has been in medical practice for some time.  But as the country searches to boost the effectiveness of traditional cancer treatments, it looks toward hyperthermia as the answer.

At a small conference sponsored by the Spanish Societies of Radiation Oncology (SEOR) Hyperthermia Group, oncologist from the area converged in Málaga, Spain, to talk about a new type of adjunct cancer treatment. They gathered to learn about the positive clinical trials and growing success that surrounds a specific type of thermal therapy, rf (radio frequency) hyperthermia. Energy is directed deep inside the body then focused and steered by adjusting wave frequency and amplitude resulting in targeted “fever” temperature (41-42C) at the tumor sight.  Heat sensitizes and improves blood flow at the tumor site, which in turn, increases the amount of chemotherapy that reaches inside the tumor. Blood flow also brings oxygen to these hypoxic (without oxygen) cancer tumors, increasing the effectiveness of radiation therapy.  Phase 3 clinical studies demonstrate that hyperthermia, along with chemotherapy or radiotherapy, increases tumor control of up to 300% when compared to radiotherapy or chemotherapy alone.

magna clinic frontThanks to regional groups like the SEOR and companies like Magna Medic, this newest cancer fighter will be available in the near future. “Facilities, like Clínica Ruber internacional (Madrid), Vithas Xanit International Hospital (Málaga), Instituto Valenciano de Oncología (Valencia) and Centro Médico Teknon (Barcelona)” are the types of progressive institutions that look for cancer treatment innovations” says Felix Navarro, Medical Physicist at the Magna Clinic Marbella, “We are very experienced with hyperthermia in our own clinic, and we look forward to sharing our successes with the country”

In preparation for the expected technology growth in hyperthermia cancer treatment sector, Magna Medic has signed a 6 year, $3 million (USD) distribution contract with hyperthermia device maker Pyrexar Medical. “We are excited to see cancer patients get the treatment they deserve” says Mark Falkowsk, Pyrexar CEO, “and we could not find a more capable partner than Magna Medic”.

ABOUT MAGNA MEDIC SYSTEMS:
Based in Málaga, Spain, Magna Medic works in the health sector specializing in technology for oncology groups. A member of SEOR hyperthermia group, the company is currently seeking hyperthermia clinical trials and is a promoter of the university masters of hyperthermia program. See them on the web at www.magnamedic.com


ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR Hyperthermia treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues. To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com.

Pyrexar Returns Hyperthermia to Egypt after 5000 years

egypt ab care signing   Dr. Kahled Dabees          Mark FalkowskiAB-Care to distribute Pyrexar Thermal Therapy line.

Salt Lake City, UT– Pyrexar Medical, leaders in thermal therapy systems for cancer treatment, announced that it has signed an exclusive distribution agreement with AB-Care Medical Technology. Based in Cairo, Egypt, AB-Care provides a wide array of medical equipment and supplies to the region via offices in Alexandria, Mansoura, Cairo and Assiut. This agreement represents a $3 million commitment to the hyperthermia product line over the next 6 years.

The first written reference to hyperthermia is found in an Egyptian papyrus scroll dating over 5000 years ago. Hyperthermia, also known as thermal therapy, is clinically proven to boost the effectiveness of radiation therapy and chemotherapy in cancer patients. Thermal therapy works by increasing blood flow and oxygenation to the tumor site.  As an adjunct therapy to radiation treatment, hyperthermia increases the number of oxygen radicals that can be produced to destroy cancer cells.  When used with chemotherapy, thermal therapy treatments sensitize the tumor site allowing more cancer killing agents to target the tumor.

Dr. Kahled Dabees, Managing Director of AB-Care Medical Technology debuted the Pyrexar product line at the Arab Health Show in Dubai this week.  Arab Health is the largest medical products show in the region attracting approx. 110,000 visitors.  “We are proud to have such a cutting edge medical technology to offer to the country,” said Dr. Dabees. “Like many countries in the region, cancer takes its toll on our population.  We strive to lead the region in superior cancer treatment technologies.”

“This year the Pyrexar team has worked at a tremendous pace to bring hyperthermia to the worldwide medical community.” said Mark Falkowski, CEO of Pyrexar Medical. “We are dedicated to this therapy and we believe that the AB-Care partnership, along with their dedicated staff, will help us achieve our goals. Once you see the clinical data, there is no way to deny the tremendous benefit hyperthermia can provide to cancer patients.”

ABOUT AB-CARE MEDICAL TECHNOLOGY
Headquartered in Cairo, Eqypt, the company was established in 2011 by tycoon medical equipment distributor KSA (Banaja Holding). The goal of the  company is to be the leader in the Egyptian Healthcare Industry by building a strong commitment to the region, targeting innovation and conducting business with the highest code of ethics. More at www.ab-care.com

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com.

Pyrexar Medical Heats up Chicago at the RSNA

rsna group

Salt Lake City, UT– Pyrexar Medical, leaders in thermal therapy systems, exhibited at the Radiological Society of North America (RSNA) Annual Meeting held last week in Chicago’s McCormick Place.

Pyrexar showcased their line of superficial, interstitial and deep regional hyperthermia systems for the treatment of cancer. Touted at the world’s largest medical device conference, the RSNA attracted radiology professionals from around the world.

Distributors from all over the world use the RSNA to learn about new technologies and to add devices to their product offering.  “I have been attending RSNA for over thirty years”, says Mark Falkowski, CEO at Pyrexar Medical.  “The relationships and introductions you make at the show are a very important part of our total marketing and sales strategy.” This year was no different as distributors from over 30 countries were in the Pyrexar booth vying for the hyperthermia line.

In a related conference event, Mark Dewhirst, DVM, PhD from Duke University Medical Center presented "Lessons Learned from XRT/Hyperthermia”.   In his presentation Dr. Dewhirst explained how hyperthermia compliments the ability of radiotherapy to kill cancer cells and reviewed the more than a dozen positive phase III cancer trials where hyperthermia was used in conjunction with radiotherapy.  He also provided new insights on how hyperthermia affects the process of DNA damage repair.

This was Pyrexar Medical’s first year at RSNA and space has already been reserved for next year’s conference in Boston.

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

Pyrexar presents at the Workshop on Hadron Therapy in Mexico

hadron therapy mexico

Hyperthermia PLUS Proton Therapy Cancer Treatment

This year’s “Workshop on Hadron Therapy” was hosted by the Mesoamerican Center for Theoretical Physics (MCTP) and FIMENUTEP (Nuclear and Medical Physics Proton Therapy) in Tuxtla Gutierrez in the state of Chiapas, Mexico.  The three-day summit brought together experts from around the world to discuss the benefits and implementation of proton therapy in the treatment of cancer.  Presenters included the Mayo Clinic, University Hospital of Geneva, John Hopkins School of Medicine and Benemérita Universidad Autónoma de Puebla (BUAP).

Mark Falkowski, CEO at Pyrexar Medical, was invited as the industry leader in thermal therpay medical devices to present the topic “Hyperthermia for Proton Therapy”.  Interest in the combined therapy was generated by a paper published in 2014 by N. Datta entitled, “Could hyperthermia with proton therapy mimic carbon ion therapy?”  This research is important as it postulates that not only could adding hyperthermia to proton therapy increase the effectiveness, but also potentially mimic the superior results of carbon ion therapy without the magnitude higher systems cost.

Currently, there is a multi-institutional phase I/II clinical trial with concomitant local hyperthermia and proton beam radiotherapy at the Kantonsspital Aarau in Switzerland. Hyperthermia is a well-known sensitizer of cancer tumors, increasing tumor response and increasing effective dose in radiation therapy.  Researchers have measured increases in tumor control and complete response in many cancers when adding hyperthermia to chemotherapy and traditional radiotherapy. The new study is designed to measure the effective increase when adding hyperthermia to proton therapy.
 
The Hadron Therapy Workshop provided another opportunity to share the hyperthermia message with medical experts, staff and university researchers focused on increasing the effectiveness of cancer treatments. Pyrexar Medical continues to ask the question, “If there is a pain-free, harm-free way to increase cancer survival rates, why not choose to use it?”

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

Pyrexar Medical brings the Thermal Therapy Message to ASTRO

ASTRO2015Salt Lake City, UT– Pyrexar Medical, leaders in thermal therapy systems, will be exhibiting at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting held in San Antonio’s Henry B. Gonzalez Convention Center on October 18-20,2015.

Pyrexar will showcase their line of superficial, interstitial and deep regional hyperthermia systems for the treatment of cancer. Clinical studies confirm that hyperthermia added to radiotherapy boosts effective dose and increases response rate without any cumulative damage to healthy tissues. Thermal Therapy is one of the most important new cancer therapies on the market and it is under-represented in the U.S.  Pyrexar will be the only manufacturer of this technology exhibiting at the show.

It has been a very big year for the newly formed Pyrexar. Since purchasing the assets from the 30-year-old device manufacturer BSD Medical, the company has experienced phenomenal growth. This growth coincides with important clinical findings supporting the use of thermal therapy, aka hyperthermia, to treat cancer. The most recent peer review (published in Cancer Treatment Reviews) of 38 clinical studies, including cancers of the bladder, breast, cervical, esophageal, head & neck, pediatric tumors, rectal and soft tissue sarcoma, concludes that adding hyperthermia to traditional cancer treatment improves outcomes by an average of 1.8.

“There is no better time to talk about the benefits of thermal therapy than now”, says Mark Falkowski, CEO at Pyrexar Medical.  “We are seeing an improvement in outcomes by adding a pain-free, harm-free treatment protocol to the standard of care.  Why wouldn’t you give that to a loved one if it could mean more time.” Pyrexar will be launching its #OneMoreYear campaign at the show, challenging everyone to think about what they would do if given one more year.

You can find Pyrexar at booth 1753 at the ASTRO show October 18, 19 & 20 and later this year at RSNA Nov. 29th - Dec 4th in Chicago. To learn more about Pyrexar products and be part of the #OneMoreYear campaign, visit www.pyrexar.com.

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

Pyrexar Helps Spain Lead the Way in Thermal Therapy

Logo Magna Medic SystemPyrexar Medical, leaders in thermal therapy systems for cancer treatment, announced that it has signed an exclusive distribution agreement with Magna Medic Systems of Spain.

Magna Medic Systems is an ESHO (European Society of Hyperthermic Oncology) partner and the driving force behind the creation of the thermal oncology working group of SEOR (Spanish Society of Radiation Oncology). SEOR is a group of 60 oncologists looking to improve cancer treatment outcomes with the latest in cancer fighting technologies.

Hyperthermia, also known as thermal therapy, is clinically proven to boost the effectiveness of radiation therapy and chemotherapy in cancer patients. Thermal therapy works by increasing blood flow and oxygenation to the tumor site.  As an adjunct therapy to radiation treatment, hyperthermia increases the number of oxygen radicals that can be produced to destroy cancer cells.  When used with chemotherapy, thermal therapy treatments sensitize the tumor site allowing more cancer killing agents to target the tumor.

According to Magna Medic general manager Elie Helou, the company has three main objectives in bringing thermal therapy to the country. 1) To improve the quality of life for those who are affected by cancer; 2) to educate the oncology community of the increased survival benefits when combining hyperthermia with radiation therapy and chemotherapy; 3) provide the best in hyperthermia technology and education to the oncology community and their patients. “After extensive market evaluation, we chose Pyrexar to help us achieve our goals,” says Mr. Helou. “We look forward to making an impact in the marketplace”.

“We are pleased to have the caliber of people at Magna Medic working with us.” said Mark Falkowski, CEO of Pyrexar Medical. “Their dedication and passion to improve cancer outcomes meshes well with our goals at Pyrexar. With their help, we will continue to promote the use of hyperthermia in Spain and throughout the region.”

ABOUT MAGNA MEDIC SYSTEMS:
Based in Málaga, Spain, Magna Medic works in the health sector specializing in technology for oncology groups. A member of SEOR hyperthermia group, the company is currently seeking hyperthermia clinical trials and is a promoter of the university masters of hyperthermia program. See them on the web at www.magnamedic.com

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com.

Pyrexar Medical Moves into New Headquarters

Interior New Pyrexar Medical Headquarter

SALT LAKE CITY – Pyrexar Medical, world leaders in thermal therapy / hyperthermia cancer treatment systems announces the company’s move to a new corporate headquarters. After five months operating in the former BSD Medical building, Pyrexar Medical has moved into its new corporate office and manufacturing facility. The new facility increases the headquarters footprint by fifty percent. The move allows for a revamped manufacturing and QC process, with additional space for research and development.

Part of the rebuilding of the hyperthermia brand includes shedding off outdated manual manufacturing processes and transferring information management to the cloud. Acquisition the of latest in ERP/MRP, CRM and CAD software, increases data stability, and brings company wide transparency from lead acquisition, thru the sales process, to delivery and service.  These investments not only increase productivity but also are aimed at keeping an eye on the bottom line.

“Creating a new workflow has been an enjoyable project for the team.” Says Mark Falkowski. “We have already reduced manufacturing time by two thirds and expect to see a significant cost reduction and immediate return on investment.”

The new building, located minutes from Salt Lake International airport, creates gateway access to the company’s worldwide distribution network; with offices in China, Japan, Taiwan, Germany, UK, South Korea, Spain, UAE, Iran, and Turkey.

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

Pyrexar helps South Korea lead the way in Cancer Therapy

Thermal Therapy reaches South Korea’s Cancer Patients

Seoul, Korea – Pyrexar Medical, leaders in thermal therapy systems for cancer treatment, announced the delivery of two new BSD-2000 Deep Regional Hyperthermia systems to prominent hospitals in South Korea.  Pyrexar’s  Field Service Manager, Ray Lauritzen, was joined by local distributor HanBeam Technology, for the onsite installation and training.  Recipients of the first BSD-2000 systems in Korea are the newly opened Healer’s Care Hospital in the city of Busan and the YCH Cancer Hospital in Seoul. Both oncology groups were looking forward to treating patients with the new systems.

South Korea has the eighth highest cancer rate in the world, just below the United States. Tracking cancer statistics in the country is the KCCR (Korea Central Cancer Registry), a nationwide hospital-based cancer registry established by the Ministry of Health and Welfare. According to the KCCR, stomach and colorectal cancer are some of the highest incidence of cancer among men and women in the country.

Hyperthermia, also known as thermal therapy, is clinically proven to boost the effectiveness of radiation therapy and chemotherapy in cancer patients. Thermal therapy works by increasing blood flow and oxygenation to the tumor site.  As an adjunct therapy to radiation treatment, hyperthermia increases the number of oxygen radicals that can be produced to destroy cancer cells.  When used with chemotherapy, thermal therapy treatments sensitize the tumor site allowing more cancer killing agents to target the tumor.

“We are certain this technology is the beginning of improved clinical outcomes in the region and we will continue to expand our market reach by working with channel partners throughout the world.” said Mark Falkowski, CEO. “Pyrexar continues to deliver the best advanced technological in the thermal therapy marketplace.”

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com.  For information about purchasing our products in South Korea, contact HanBeamTek.com

News Archive

  • PYREXAR Medical Acquires Hyperthermia Assets of BSD Medical +

    Promising Cancer Treatment Technology Now Under New Leadership Salt Lake Read More
  • Pyrexar Medical closes deal with HanBeam Technology +

    Hyperthermia products find distribution in South Korea Salt Lake City, Read More
  • Pyrexar Chief Scientist Goes to China +

    PYREXAR HT Hyperthermia products find distribution with Orientech SALT LAKE Read More
  • Pyrexar Medical expands Hyperthermia to Central Asia +

    PYREXAR HT Hyperthermia products find distribution with ORB Corporation SALT Read More
  • Pyrexar brings the Fight Against Cancer to South Korea +

    Pyrexar receives final authorization to sell Thermal Therapy devices in Read More
  • 1
  • 2
  • 3

Contact Info

We are pleased to hear from you. If we can help you with Pyrexar HT products, Clinical Studies or the Advancement of Hyperthermia. We would love to hear what you have to say.

Telephone

+1-(844)-797-3927


Address

1825 West Research Way, Ste E
Salt Lake City, UT 84119, USA

Spread the word about Hyperthermia.

facebooktwittergoogleplus